Применение биологических и таргетных синтетических базисных противовоспалительных препаратов у пациентов пожилого возраста с ревматоидным артритом: за и против

В связи с глобальным старением населения и увеличением продолжительности жизни растет доля пожилых пациентов с ревматоидным артритом — как за счет пациентов с дебютом после 60 лет, так и пожилых пациентов, у которых заболевание стартовало в молодом возрасте. Лечение таких пациентов сопряжено с рядом сложностей, что связано с особенностями старения иммунной системы и организма в целом, бременем коморбидных состояний. Пожилые пациенты, в отличие от молодых, имеют более высокие риски развития нежелательных явлений при назначении как синтетических, так и биологических препаратов. Эти особенности ведут к более щадящей стратегии лечения пожилых пациентов, ограничению применения адекватных доз базисных препаратов и низкому числу назначения биологических препаратов. В данной статье приводятся актуальные данные о безопасности и эффективности применения биологических и таргетных синтетических базисных противовоспалительных препаратов у пожилой категории пациентов с ревматоидным артритом.

1. Safiri S, Kolahi A, Hoy D, Smith E, Bettampadi D, Mansournia MEA. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 2019;215920. https://doi.org/10.1136/annrheumdis-2019-215920.

2. Krams T, Ruyssen-Witrand A, Nigon D, Degboe Y, Tobon G, Fautrel B, Berenbaum F, Cantagrel A, Constantin A. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. Joint Bone Spine. 2016 Oct;83(5):511-5. doi: 10.1016/j.jbspin.2015.09.010. Epub 2016 Mar 15. PMID: 26992954.

3. Rasch E, Hirsch R, Paulose-Ram R, Hochberg M. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917–26. https://doi.org/10.1002/art.10897.

4. Marín JS, Mazenett-Granados EA, Salazar-Uribe JC, Sarmiento M, Suárez JF, Rojas M, Munera M, Pérez R, Morales C, Dominguez JI, Anaya JM. Increased incidence of rheumatoid arthritis after COVID-19. Autoimmun Rev. 2023 Oct;22(10):103409. doi: 10.1016/j.autrev.2023.103409. Epub 2023 Aug 18. PMID: 37597602.

5. Ke Y, Dai X, Xu D, Liang J, Yu Y, Cao H, Chen W, Lin J. Features and Outcomes of Elderly Rheumatoid Arthritis: Does the Age of Onset Matter? A Comparative Study From a Single Center in China. Rheumatol Ther. 2021 Mar;8(1):243-254. doi: 10.1007/s40744-020-00267-8. Epub 2020 Dec 14. PMID: 33315188; PMCID: PMC7991049.

6. Rink L, Cakman I, Kirchner H.. Altered cytokine production in the elderly. Mech Ageing Dev 1998;102:199–209.

7. Panda A, Arjona A, Sapey E. et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009;30:325–33.

8. Siegrist CA, Aspinall R.. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9:185–94.

9. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB.. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011;10:330–5.

10. Boraschi D, Aguado MT, Dutel C. et al. The gracefully aging immune system. Sci Transl Med 2013;5:185ps8.

11. Pawelec G. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics. EMBO Rep. 2007 Mar;8(3):220-3. doi: 10.1038/sj.embor.7400922. Epub 2007 Feb 16. PMID: 17304236; PMCID: PMC1808042.

12. Gao Y, Cai W, Zhou Y, Li Y, Cheng J, Wei F. Immunosenescence of T cells: a key player in rheumatoid arthritis. Inflamm Res. 2022 Dec;71(12):1449-1462. doi: 10.1007/s00011-022-01649-0. Epub 2022 Oct 25. PMID: 36280621.

13. Siegrist CA, Aspinall R.. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009;9:185–94.

14. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):990-7. doi: 10.1002/acr.22281. PMID: 24470378; PMCID: PMC5059836.

15. Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev. 2020 Jun;19(6):102528. doi: 10.1016/j.autrev.2020.102528. Epub 2020 Mar 29. PMID: 32234572.

16. Chen YM, Chen LK, Lan JL, Chen DY. Geriatric syndromes in elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Oct;48(10):1261-4. doi: 10.1093/rheumatology/kep195. Epub 2009 Aug 3. PMID: 19651885.

17. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–2300. doi: 10.1002/art.10529.

18. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293. doi: 10.1002/art.10524.

19. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66(3):308–312. doi: 10.1136/ard.2006.057265.

20. Bernatsky S., Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: Analysis of administrative health databases in Québec, Canada. Drugs Aging. 2008;25:879–884. doi: 10.2165/00002512-200825100-00007.

21. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226–1229. doi: 10.1136/ard.2005.051144.

22. Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford) 2014;53(4):671–677. doi: 10.1093/rheumatology/ket399.

23. Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48(8):906–910. doi: 10.1093/rheumatology/kep129.

24. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57(6):928–934. doi: 10.1002/art.22890.

25. 20Genevay S, Finckh A, Ciurea A et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;57:679–85.

26. Radovits BJ, Kievit W, Fransen J et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1470–3.

27. Genevay S., Finckh A., Ciurea A., Chamot A.M., Kyburz D., Gabay C. Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: A population-based cohort study. Arthritis Rheum. 2007;57:679–685. doi: 10.1002/art.22688.

28. Radovits B.J., Kievit W., Fransen J., van de Laar M.A., Jansen T.L., van Riel P.L., Laan R.F. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 2009;68:1470–1473. doi: 10.1136/ard.2008.094730

29. Jinno S., Onishi A., Dubreuil M., Akashi K., Hashimoto M., Yamamoto W., Murata K., Takeuchi T., Kotani T., Maeda Y., et al. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: The ANSWER cohort study. Rheumatol. Int. 2020;40:1987–1995. doi: 10.1007/s00296-020-04660-y.

30. Okazaki M, Kobayashi H, Ishii Y et al. Real-world treatment patterns for golimumab and concomitant medications in Japanese rheumatoid arthritis patients. Rheumatol Ther 2018;5:185–201.

31. Torrente-Segarra V, Fernandez Prada M, Exposito Moliner R et al. How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol. Rheumatol Int 2019;39:395–8.

32. Ochi S., Saito K., Mizoguchi F., Kato S., Tanaka Y. Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: A retrospective cohort study. Arthritis Res. Ther. 2020;22:41. doi: 10.1186/s13075-020-2122-5.

33. Murata K., Ito H., Hashimoto M., Nishitani K., Murakami K., Tanaka M., Yamamoto W., Mimori T., Matsuda S. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int. J. Rheum. Dis. 2019;22:1084–1093. doi: 10.1111/1756-185X.13428.

34. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24(3):239–254. doi: 10.2165/00002512-200724030-00005.

35. Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford) 2009;48(12):1575–1580. doi: 10.1093/rheumatology/kep291.

36. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234–243.

37. Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2020 Sep 1;59(9):2563-2571. doi: 10.1093/rheumatology/kez671. Erratum in: Rheumatology (Oxford). 2021 Apr 6;60(4):2033. PMID: 31998962; PMCID: PMC7449803.

38. Ochi S., Mizoguchi F., Nakano K., Tanaka Y. Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. J. Rheumatol. 2021;48:1655–1662. doi: 10.3899/jrheum.201135.

39. Chen D.Y., Hsieh T.Y., Chen Y.M., Hsieh C.W., Lan J.L., Lin F.J. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: A comparison with younger-onset disease. Gerontology. 2009;55:250–258. doi: 10.1159/000164393.

40. Filippini M, Bazzani C, Favalli EG et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010;38:90–6.

41. Majithia V, Peel C, Geraci SA. Rheumatoid arthritis in elderly patients. Geriatrics 2009;64:22–8.

42. Widdifield J, Bernatsky S, Paterson JM et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013;65:353–61.

43. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007;24:239–54.

44. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124–31.

45. Toh S, Li L, Harrold LR et al. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf 2012;21:524–34.

46. Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology 2016;55:523–34.

47. Du Pan SM, Dehler S, Ciurea A et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560–8.

48. Widdifield J, Bernatsky S, Paterson JM et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013;65:353–61.

49. Schneeweiss S, Setoguchi S, Weinblatt ME et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754–64.

50. McDonald JR, Zeringue AL, Caplan L et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009;48:1364–71.

51. Iwanaga N, Arima K, Terada K et al. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study. Int J Rheum Dis 2017;20:346–52.

52. Nurmohamed M, Bao Y, Signorovitch J et al. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open 2015;1:e000080.

53. Setoguchi S, Schneeweiss S, Avorn J et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008;156:336–41.

54. Zhang J, Xie F, Yun H et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1813–8.

55. Haynes K, Beukelman T, Curtis JR et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48–58.

56. M. Gema Bonilla-Herna et al. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology 2011;50:1542-1550 http://dx.doi.org/doi:10.1093/rheumatology/ker192

57. Novella-Navarro M., Balsa A. Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients. Drugs Aging. 2022;39:841–849. doi: 10.1007/s40266-022-00976-5.

58. Ochi S., Sonomoto K., Nakayamada S., Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry. Arthritis Res. Ther. 2022;24:61. doi: 10.1186/s13075-022-02744-7.

59. Ytterberg S.R., Bhatt D.L., Mikuls T.R., Koch G.G., Fleischmann R., Rivas J.L., Germino R., Menon S., Sun Y., Wang C., et al. ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N. Engl. J. Med. 2022;386:316–326. doi: 10.1056/NEJMoa2109927.

60. Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023 Feb;82(2):182-188. doi: 10.1136/ard-2022-222824. Epub 2022 Oct 5. Erratum in: Ann Rheum Dis. 2023 Nov;82(11):e222. PMID: 36198438.

61. Curtis J.R., Schulze-Koops H., Takiya L., Mebus C.A., Terry K.K., Biswas P., Jones T.V. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2017;35:390–400.

62. Fleischmann R., Alam J., Arora V., Bradley J., Schlichting D.E., Muram D., Smolen J.S. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017;3:e000546. doi: 10.1136/rmdopen-2017-000546.

63. Fleischmann R, Alam J, Arora V, Bradley J, Schlichting DE, Muram D, Smolen JS. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017 Oct 10;3(2):e000546. doi: 10.1136/rmdopen-2017-000546. PMID: 29071120; PMCID: PMC5640108.

64. Genovese M.C., Kalunian K., Gottenberg J.E., Mozaffarian N., Bartok B., Matzkies F., Gao J., Guo Y., Tasset C., Sundy J.S., et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019;322:315–325. doi: 10.1001/jama.2019.9055.

65. Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. PMID: 37308218; PMCID: PMC10423494.

66. Chen DY, Hsieh TY, Chen YM et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 2009;55:250–8.

67. Punzi L., Bertazzolo N., Pianon M., Rizzi E., Rossini P., Todesco S. Synovial fluid levels of proinflammatory interleukins and their inter-relationships in elderly vs younger onset rheumatoid arthritis. Aging. 1996;8:277–281. doi: 10.1007/BF03339579.

68. Burmester GR, Choy E, Kivitz A et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:1078–85.

69. Pers Y.M., Schaub R., Constant E., Lambert J., Godfrin-Valnet M., Fortunet C., Bourichi W., Prades B.P., Wendling D., Gaudin P., et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Jt. Bone Spine. 2015;82:25–30. doi: 10.1016/j.jbspin.2014.07.010.

70. Kawabe A, Nakano K, Kubo S et al. Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Res Ther 2020;22:136.

71. Strang AC, Bisoendial RJ, Kootte RS et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 2013;229:174–81.

72. Yun H, Xie F, Delzell E et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res 2015;67:731–6.

73. Ebina K, Hashimoto M, Yamamoto W et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis—the ANSWER cohort study. PLoS One 2019;14:e0216624.

74. Rutherford A.I., Subesinghe S., Hyrich K.L., Galloway J.B. Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann. Rheum. Dis. 2018;77:905–910. doi: 10.1136/annrheumdis-2017-212825.

75. Jinno S., Onishi A., Dubreuil M., Hashimoto M., Yamamoto W., Murata K., Takeuchi T., Kotani T., Maeda Y., Ebina K., et al. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Arthritis Res. Ther. 2021;23:116. doi: 10.1186/s13075-021-02496-w.

76. Pawar A., Desai R.J., Solomon D.H., Santiago Ortiz A.J., Gale S., Bao M., Sarsour K., Schneeweiss S., Kim S.C. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study. Ann. Rheum. Dis. 2019;78:456–464. doi: 10.1136/annrheumdis-2018-214367.

77. Mori S., Yoshitama T., Hidaka T., Sakai F., Hasegawa M., Hashiba Y., Suematsu E., Tatsukawa H., Mizokami A., Yoshizawa S., et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS ONE. 2017;12:e0179179. doi: 10.1371/journal.pone.0179179.

78. Sarilumab (Kevzara) for polymyalgia rheumatica. Med Lett Drugs Ther. 2024 May 13;66(1702):77-78. doi: 10.58347/tml.2024.1702c. PMID: 38696312.

79. Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452. PMID: 37792612.

80. Lomakin NV, Bakirov BA, Protsenko DN, Mazurov VI, Musaev GH, Moiseeva OM, Pasechnik ES, Popov VV, Smolyarchuk EA, Gordeev IG, Gilyarov MY, Fomina DS, Seleznev AI, Linkova YN, Dokukina EA, Eremeeva AV, Pukhtinskaia PS, Morozova MA, Zinkina-Orikhan AV, Lutckii AA. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. Inflamm Res. 2021 Dec;70(10-12):1233-1246. doi: 10.1007/s00011-021-01507-5. Epub 2021 Sep 29. PMID: 34586459; PMCID: PMC8479713.

81. Antonov VN, Ignatova GL, Pribytkova OV, Sleptsova SS, Strebkova EA, Khudyakova EA, Simakov AI, Rabets SY, Tikhonova EP, Kurmaeva DY, Petrushin MA, Mashkov AS, Gayazova EV, Yasheva IV, Andreev MA, Khinovker VV, Karpunin AY, Berezhanskiy BV. [Experience of olokizumab use in COVID-19 patients]. Ter Arkh. 2020 Dec 15;92(12):148-154. Russian. doi: 10.26442/00403660.2020.12.200522. PMID: 33720587.

82. Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs. 2024 Jan;38(1):61-71. doi: 10.1007/s40259-023-00634-1. Epub 2023 Nov 21. PMID: 37989892; PMCID: PMC10789669.

83. Wendler J, Burmester GR, Sorensen H et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2484 patients. Arthritis Res Ther 2014;16:R80.

84. Payet S, Soubrier M, Perrodeau E et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res 2014;66:1289–95.

85. van Vollenhoven RF, Fleischmann RM, Furst DE et al. Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. J Rheumatol 2015;42:1761–6.

86. Ekin A, Coskun BN, Dalkilic E, Pehlivan Y. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. Ir J Med Sci. 2023 Aug;192(4):1959-1973. doi: 10.1007/s11845-022-03193-6. Epub 2022 Oct 19. PMID: 36258064; PMCID: PMC9579651.

87. Al-Adhoubi NK, Ali M, Wahshi HA, Salmi IA, Al-Balushi F, Lawati TA, Mohammed A, Muqbali AA, Kalbani HA, Al-Abrawi S, Khamis F. COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern. Curr Rheumatol Rev. 2022;18(3):234-242. doi: 10.2174/1573397118666220412114514. PMID: 35418287.

88. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018 Nov 2;1(7):e184169. doi: 10.1001/jamanetworkopen.2018.4169. PMID: 30646343; PMCID: PMC6324375.

89. Ebina K, Hashimoto M, Yamamoto W et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis—the ANSWER cohort study. PLoS One 2019;14:e0216624.

90. Lahaye C, Soubrier M, Mulliez A et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology 2016;55:874–82.

91. Zhang J, Xie F, Delzell E et al. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res 2015;67:624–32.

92. Sekiguchi M, Fujii T, Matsui K et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD study. J Rheumatol 2016;43:1974–83.

93. Jinno S., Onishi A., Dubreuil M., Akashi K., Hashimoto M., Yamamoto W., Murata K., Takeuchi T., Kotani T., Maeda Y., et al. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: The ANSWER cohort study. Rheumatol. Int. 2020;40:1987–1995. doi: 10.1007/s00296-020-04660-y.

94. Chen SK, Liao KP, Liu J et al. Risk of hospitalized infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. Arthritis Care Res 2020;72:9–17.WorldCat

95. Yun H, Xie F, Delzell E et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 2016;68:56–66.

96. Salmon JH, Gottenberg JE, Ravaud P et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 2016;75:1108–13.

97. Arts EE, Fransen J, Den Broeder AA, van Riel PLCM, Popa CD. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017 Oct;76(10):1693-1699. doi: 10.1136/annrheumdis-2016-210997. Epub 2017 Jun 12. PMID: 28606965.

98. De Germay S, Bagheri H, Despas F et al. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology 2020;59:2360–7.

99. Weinblatt ME, Moreland LW, Westhovens R et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013;40:787–97.